Nephropathy - Pipeline Review, H1 2016

  • ID: 3714980
  • Report
  • 59 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Baxalta Incorporated
  • ChemoCentryx, Inc.
  • Complexa, Inc.
  • Omeros Corporation
  • Promedior, Inc.
  • MORE
Nephropathy - Pipeline Review, H1 2016

Summary

‘Nephropathy - Pipeline Review, H1 2016’, provides an overview of the Nephropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nephropathy and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nephropathy
- The report reviews pipeline therapeutics for Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Nephropathy therapeutics and enlists all their major and minor projects
- The report assesses Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Nephropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Nephropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nephropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Baxalta Incorporated
  • ChemoCentryx, Inc.
  • Complexa, Inc.
  • Omeros Corporation
  • Promedior, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Nephropathy Overview

Therapeutics Development

Pipeline Products for Nephropathy - Overview

Nephropathy - Therapeutics under Development by Companies

Nephropathy - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Nephropathy - Products under Development by Companies

Nephropathy - Companies Involved in Therapeutics Development

Baxalta Incorporated

ChemoCentryx, Inc.

Complexa, Inc.

Omeros Corporation

Promedior, Inc.

Nephropathy - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

CCX-168 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CXA-10 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

imatinib mesylate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OMS-721 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PRM-151 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

R-190 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

R-801 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

R-901 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SM-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit Casein Kinase 2 for Cancer and Nephritis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Nephropathy - Recent Pipeline Updates

Nephropathy - Dormant Projects

Nephropathy - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Nephropathy, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Nephropathy - Pipeline by Baxalta Incorporated, H1 2016

Nephropathy - Pipeline by ChemoCentryx, Inc., H1 2016

Nephropathy - Pipeline by Complexa, Inc., H1 2016

Nephropathy - Pipeline by Omeros Corporation, H1 2016

Nephropathy - Pipeline by Promedior, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Nephropathy Therapeutics - Recent Pipeline Updates, H1 2016

Nephropathy - Dormant Projects, H1 2016

Nephropathy - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Nephropathy, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Baxalta Incorporated
ChemoCentryx, Inc.
Complexa, Inc.
Omeros Corporation
Promedior, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll